Daniel Faga R.'s most recent trade in AnaptysBio Inc was a trade of 26,838 Restricted Stock Unit done . Disclosure was reported to the exchange on Jan. 7, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 26,838 | 80,512 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 26,838 | 493,625 (1%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 44.71 per share. | 07 Jan 2026 | 14,281 | 479,344 (1%) | 0% | 44.7 | 638,504 | Common Stock |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 133,400 | 133,400 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 98,600 | 98,600 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 17,850 | 17,850 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 17,850 | 475,989 (1%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 45.11 per share. | 06 Jan 2026 | 9,202 | 466,787 (1%) | 0% | 45.1 | 415,102 | Common Stock |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2026 | 34,677 | 69,355 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2026 | 34,677 | 473,448 (1%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 43.26 per share. | 03 Jan 2026 | 15,309 | 458,139 (1%) | 0% | 43.3 | 662,267 | Common Stock |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 305,500 | 305,500 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 107,350 | 107,350 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 34,678 | 438,036 (1%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 34,678 | 104,032 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 17,850 | 442,853 (1%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 17,850 | 35,700 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.60 per share. | 03 Jan 2025 | 13,033 | 425,003 (1%) | 0% | 14.6 | 190,282 | Common Stock |
| AnaptysBio Inc | Daniel R. Faga | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.30 per share. | 03 Jan 2025 | 6,387 | 436,466 (1%) | 0% | 15.3 | 97,721 | Common Stock |
| AnaptysBio Inc | Daniel R. Faga | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 160,000 | 160,000 | - | - | Common Stock | |
| AnaptysBio Inc | Daniel R. Faga | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.60 per share. | 22 Mar 2024 | 347,441 | 401,646 (1%) | 1% | 21.6 | 7,504,726 | Common Stock |
| AnaptysBio Inc | Daniel R. Faga | Director, CEO | Sale of securities on an exchange or to another person at price $ 22.78 per share. | 22 Mar 2024 | 145,940 | 752,087 (2%) | 0% | 22.8 | 3,325,185 | Common Stock |
| AnaptysBio Inc | Daniel R. Faga | Director, CEO | Sale of securities on an exchange or to another person at price $ 21.42 per share. | 22 Mar 2024 | 3,000 | 749,087 (2%) | 0% | 21.4 | 64,268 | Common Stock |
| AnaptysBio Inc | Daniel Faga R. | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 17,850 | 904,893 (3%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | Daniel R. Faga | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 17,850 | 53,550 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Daniel R. Faga | Director, CEO | Sale of securities on an exchange or to another person at price $ 21.81 per share. | 06 Jan 2024 | 6,866 | 898,027 (3%) | 0% | 21.8 | 149,747 | Common Stock |
| AnaptysBio Inc | R. Daniel Faga | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 379,620 | 379,620 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | R. Faga Daniel | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 138,710 | 138,710 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Daniel R. Faga | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 194,900 | 194,900 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Daniel R. Faga | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 71,400 | 71,400 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Daniel R. Faga | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2022 | 887,043 | 887,043 (3%) | 3% | 0 | Common Stock | |
| AnaptysBio Inc | Daniel R. Faga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 9,200 | 9,200 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Daniel R. Faga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Nov 2021 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| AnaptysBio Inc | Daniel R. Faga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Nov 2021 | 2,321 | 2,321 | - | - | Stock Option (Right to Buy) |